TITLE

First oral thrombin inhibitor enters market: Drug does not require clinicians to monitor INR

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
December 2010
SOURCE
American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1974
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the marketing of dabigatran etexilate or Pradaxa. According to Boehringer Ingelheim Pharmaceuticals Inc., the drug prevents stroke and systematic embolism in patients with nonvalvular atrial fibrillation. It says that clinician Snehal B. Bhatt would not recommend dabigatran etexilate therapy for patients with a peptic ulcer disease history or gastroesophageal reflux disease.
ACCESSION #
55612472

 

Related Articles

  • Apixaban superior to warfarin in trial. Elliott, William T. // Infectious Disease Alert;Feb2013 Pharmacology Watch, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved apixaban, a novel oral anticoagulant), for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).

  • Apixaban and Rivaroxaban Near Approval for Nonvalvular AF.  // Clinical Cardiology Alert;Apr2011 Pharmacology, p1 

    The article reports the probable approval of rivaroxaban and apixaban (direct factor Xa inhibitors) for stroke prevention in patients with nonvalvular atrial fibrillation (AF), in line with the Food and Drug Administration (FDA) approval of dabigatran, a direct thrombin inhibitor. It cites a...

  • Dabigatran for stroke in patients with nonvalvular atrial fibrillation. Elliott, William T. // Critical Care Alert;Apr2011 Pharmacology, p1 

    The article reports that dabigatran, a direct thrombin inhibitor, has been approved by the FDA for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and that the approval of apixaban and rivaroxaban, both direct factor Xa inhibitors, is in the offing.

  • FDA Approves Apixaban for Patients with Nonvalvular AF. Elliott, William T. // Internal Medicine Alert;1/29/2013, Vol. 35 Issue 2, Special section p1 

    The article reports that the Food and Drug Administration (FDA) had approved the use of the drug Apixaban for patients with nonvalvular atrial fibrillation (AF).

  • Apixaban superior to warfarin in trial. Elliott, William T. // Neurology Alert;Feb2013 Pharmacology Watch, p1 

    The article reports on the approval made by the U.S. Food and Drug Administration for apixaban third novel oral anticoagulant marketed by Eliquis by Bristol-Myers Squibb and Pfizer, for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).

  • Warfarin Replacement? Bassett, Mike // Today's Geriatric Medicine;Nov/Dec2013, Vol. 6 Issue 6, p16 

    The article offers information on alternative drugs to warfarin to prevent Atrial fibrillation (AFib) in older adults. Topics include anticoagulants approved by the Food and Drug Administration (FDA) including rivaroxaban (Xarelto), dabigatran (Praxada) and apixaban (Eliquis). It also discusses...

  • Dabigatran Leading Race to Replace Warfarin. Elliott, William T. // Clinical Oncology Alert;Nov2010 Supplement, p1 

    This article reports on the impending approval of Boehringer Ingelheim's dabigratran by the U.S. Food and Drug Administration (FDA). In September 2010, the FDA's Cardiovascular and Renal Drugs Advisory Committee recommended the approval of the drug which is indicated for preventing stroke and...

  • New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: More Choices Bring More Challenges. Howard, Patricia A. // Hospital Pharmacy;May2013, Vol. 48 Issue 5, p366 

    For patients with atrial fibrillation, anticoagulant therapy is essential to reduce the risk of ischemic stroke that is associated with this arrhythmia. Historically, warfarin has been the preferred treatment for patients at moderate to high risk despite many potential limitations. With the...

  • FDA actions. Elliott, William T. // Critical Care Alert;Dec2010 Pharmacology, p2 

    The article offers information on the actions taken by the U.S. Food and Drug Administration (FDA), including the approval of fingolimod as treatment for multiple sclerosis' relapsing forms, labeling change order for bisphosphonates, and approval of dabigatran for blood clots and stroke...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics